A Phase 1 Open Label, Multi-Center Study to Evaluate the Safety and Tolerability of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)
Latest Information Update: 26 May 2023
At a glance
- Drugs Saposin C (Primary)
- Indications Diffuse intrinsic pontine glioma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms KONQUER
- Sponsors Bexion Pharmaceuticals
- 03 Oct 2022 Planned End Date changed from 1 Oct 2023 to 1 Dec 2024.
- 03 Oct 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Dec 2023.
- 16 Jun 2022 Planned End Date changed from 1 May 2023 to 1 Oct 2023.